Expression of estrogen and androgen receptors in differentiated thyroid cancer: An additional criterion to assess the patient's risk

Endocrine-Related Cancer

Volumn 19, Issue 4, 2012, Pages 463-471

  Magri, Flavia ^a   Capelli, Valentina ^a   Rotondi, Mario ^a   Leporati, Paola ^a   La Manna, Luigi ^b   Ruggiero, Rubina ^b   Malovini, Alberto ^b   Bellazzi, Riccardo ^a   Villani, Laura ^a   Chiovato, Luca ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b IRCCS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; LIOTHYRONINE; RADIOACTIVE IODINE; THYROGLOBULIN; THYROGLOBULIN ANTIBODY; THYROTROPIN; THYROTROPIN RECEPTOR; THYROXINE;

ABLATION THERAPY; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER INVASION; CANCER PROGNOSIS; CANCER RISK; CANCER STAGING; CHEMOLUMINESCENCE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIFFERENTIATED THYROID CANCER; DISEASE ASSOCIATION; FEMALE; FREE LIOTHYRONINE INDEX; FREE THYROXINE INDEX; HISTOPATHOLOGY; HORMONE RELEASE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INCIDENTAL FINDING; LIOTHYRONINE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; SEX RATIO; THYROGLOBULIN BLOOD LEVEL; THYROID GLAND; THYROID TUMOR; THYROTROPIN BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; CASE-CONTROL STUDIES; CELL DIFFERENTIATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; RECEPTORS, ANDROGEN; RECEPTORS, ESTROGEN; RISK FACTORS; THYROGLOBULIN; THYROID NEOPLASMS; YOUNG ADULT;

EID: 84864406758     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-11-0389     Document Type: Article

References (39)

1. Ahmad N & Kumar R 2011 Steroid hormone receptors in cancer development: a target for cancer therapeutics. Cancer Letters 300 1-9. (doi:10.1016/j.canlet.2010.09.008)
2. Badve S & Nakshatri H 2009 Oestrogen-receptor-positive breast cancer: towards bridging histopathological and molecular classifications. Journal of Clinical Pathology 62 6-12. (doi:10.1136/jcp.2008.059899)
3. Banu KS, Govindarajulu P & Aruldhas MM 2001 Testosterone and estradiol have specific differential modulatory effect on the proliferation of human thyroid papillary and follicular carcinoma cell lines independent of TSH action. Endocrine Pathology 12 315-327. (doi:10.1385/EP:12:3:315)
4. Banu SK, Govindarajulu P & Aruldhas MM 2002 Testosterone and estradiol differentially regulate TSH-induced thyrocyte proliferation in immature and adult rats. Steroids 67 573-579. (doi:10.1016/S0039-128X(02)00008- 9)
5. Bardin A, Boulle N, Lazennec G, Vignon F & Pujol P 2004 Loss of ERbeta expression as a common step in estrogen-dependent tumor progression. Endocrine-Related Cancer 11 537-551. (doi:10.1677/erc.1.00800)
6. Barone M, Lofano K, De Tullio N, Licino R, Albano F & Di Leo A 2012 Dietary, endocrine, and metabolic factors in the development of colorectal cancer. Journal of Gastrointestinal Cancer 43 13-19. (doi:10.1007/s12029-011- 9332-7)
7. Brassard M, Borget I, Edet-Sanson A, Giraudet AL, Mundler O, Toubeau M, Bonichon F, Borson-Chazot F, Leenhardt L, Schvartz C et al. 2011 Long-term follow-up of patients with papillary and follicular thyroid cancer: a prospective study on 715 patients. Journal of Clinical Endocrinology and Metabolism 96 1352-1359. (doi:10.1210/jc.2010-2708)
8. Chen GG, Vlantis AC, Zeng Q & van Hasselt CA 2008 Regulation of cell growth by estrogen signaling and potential targets in thyroid cancer. Current Cancer Drug Targets 8 367-377. (doi:10.2174/156800908785133150)
9. Clarke RB 2003 Steroid receptors and proliferation in the human breast. Steroids 68 789-794. (doi:10.1016/S0039-128X(03)00122-3)
10. Clemons M & Goss P 2001 Estrogen and the risk of breast cancer. New England Journal of Medicine 344 276-285. (doi:10.1056/NEJM200101253440407)
11. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Sherman SI, Tuttle RM et al. 2006 Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 16 109-142. (doi:10.1089/thy.2006.16.109)
12. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M et al. 2009 Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19 1167-1214. (doi:10.1089/thy.2009.0110)
13. Fox EM, Davis RJ & Shupnik MA 2008 ERbeta in breast cancer - onlooker, passive player, or active protector? Steroids 73 1039-1051. (doi:10.1016/j.steroids.2008.04.006)
14. Giovanella L, Ceriani L & Ghelfo A 2007 Redefining functional sensitivity of thyroglobulin assay on Immulite platform: implications in thyroid cancer management. Clinical Chemistry and Laboratory Medicine 45 1523-1524. (doi:10.1515/CCLM.2007.309)
15. Heinlein CA & Chang C 2004 Androgen receptor in prostate cancer. Endocrine Reviews 25 276-308. (doi:10.1210/er.2002-0032)
16. Jemal A, Siegel R, Xu J & Ward E 2010 Cancer statistics, 2010. CA: A Cancer Journal for Clinicians 60 277-300. (doi:10.3322/caac.20073)
17. Kansakar E, Chang YJ, Mehrabi M & Mittal V 2009 Expression of estrogen receptor, progesterone receptor, and vascular endothelial growth factor-A in thyroid cancer. American Surgeon 75 785-789 (discussion 789).
18. Kumar R & Thompson EB 1999 The structure of the nuclear hormone receptors. Steroids 64 310-319. (doi:10.1016/S0039-128X(99)00014-8)
19. Lee ML, Chen GG, Vlantis AC, Tse GM, Leung BC & van Hasselt CA 2005 Induction of thyroid papillary carcinoma cell proliferation by estrogen is associated with an altered expression of Bcl-xL. Cancer Journal 11 113-121. (doi:10.1097/00130404-200503000-00006)
20. Lin JD, Huang MJ, Hsu BR, Chao TC, Hsueh C, Liu FH, Liou MJ & Weng HF 2002 Significance of postoperative serum thyroglobulin levels in patients with papillary and follicular thyroid carcinomas. Journal of Surgical Oncology 80 45-51. (doi:10.1002/jso.10089)
21. Mack WJ, Preston-Martin S, Bernstein L, Qian D & Xiang M 1999 Reproductive and hormonal risk factors for thyroid cancer in Los Angeles County females. Cancer Epidemiology, Biomarkers & Prevention 8 991-997.
22. Manole D, Schildknecht B, Gosnell B, Adams E & Derwahl M 2001 Estrogen promotes growth of human thyroid tumor cells by different molecular mechanisms. Journal of Clinical Endocrinology and Metabolism 86 1072-1077. (doi:10.1210/jc.86.3.1072)
23. Mete O & Asa SL 2011 Pathological definition and clinical significance of vascular invasion in thyroid carcinomas of follicular epithelial derivation. Modern Pathology 24 1545-1552. (doi:10.1038/modpathol.2011.119)
24. Negri E, Dal Maso L, Ron E, La Vecchia C, Mark SD, Preston-Martin S, McTiernan A, Kolonel L, Yoshimoto Y, Jin F et al. 1999 A pooled analysis of case-control studies of thyroid cancer. II. Menstrual and reproductive factors. Cancer Causes & Control 10 143-155. (doi:10.1023/A:1008880429862)
25. Pellegriti G, Scollo C, Lumera G, Regalbuto C, Vigneri R & Belfiore A 2004 Clinical behavior and outcome of papillary thyroid cancers smaller than 1.5 cm in diameter: study of 299 cases. Journal of Clinical Endocrinology and Metabolism 89 3713-3720. (doi:10.1210/jc.2003-031982)
26. Persson I, Yuen J, Bergkvist L & Schairer C 1996 Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy - long-term follow-up of a Swedish cohort. International Journal of Cancer 67 327-332. (doi:10.1002/(SICI)1097-0215(19960729)67:3〈327::AID- IJC4〉3.0.CO;2-T)
27. Pham TM, Fujino Y, Mikami H, Okamoto N, Hoshiyama Y, Tamakoshi A, Matsuda S & Yoshimura T 2009 Reproductive and menstrual factors and thyroid cancer among Japanese women: the Japan Collaborative Cohort Study. Journal of Women's Health 18 331-335. (doi:10.1089/jwh.2008.1038)
28. Pisanu A, Reccia I, Nardello O & Uccheddu A 2009 Risk factors for nodal metastasis and recurrence among patients with papillary thyroid microcarcinoma: differences in clinical relevance between nonincidental and incidental tumors. World Journal of Surgery 33 460-468. (doi:10.1007/s00268-008- 9870-8)
29. Rades D, Setter C, Dahl O, Schild SE & Noack F 2012 The prognostic impact of tumor cell expression of estrogen receptor-alpha, progesterone receptor, and androgen receptor in patients irradiated for non-small cell lung cancer. Cancer 118 157-163. (doi:10.1002/cncr.26282)
30. Rajoria S, Suriano R, Shanmugam A, Wilson YL, Schantz SP, Geliebter J & Tiwari RK 2010 Metastatic phenotype is regulated by estrogen in thyroid cells. Thyroid 20 33-41. (doi:10.1089/thy.2009.0296)
31. Rajoria S, Suriano R, George AL, Shanmugam A, Jussim C, Shin EJ, Moscatello AL, Geliebter J, Carpi A & Tiwari RK 2011 Estrogen activity as a preventive and therapeutic target in thyroid cancer. Biomedicine & Pharmacotherapy 66 151-158. (doi:10.1016/j.biopha.2011.11.010)
32. Simoncini T & Genazzani AR 2003 Non-genomic actions of sex steroid hormones. European Journal of Endocrinology 148 281-292. (doi:10.1530/eje.0. 1480281)
33. Stanisic V, Lonard DM & O'Malley BW 2010 Modulation of steroid hormone receptor activity. Progress in Brain Research 181 153-176.
34. Stanley JA, Aruldhas MM, Chandrasekaran M, Neelamohan R, Suthagar E, Annapoorna K, Sharmila S, Jayakumar J, Jayaraman G, Srinivasan N et al. 2012 Androgen receptor expression in human thyroid cancer tissues: a potential mechanism underlying the gender bias in the incidence of thyroid cancers. Journal of Steroid Biochemistry and Molecular Biology 130 105-124. (doi:10.1016/j.jsbmb.2012.02.004)
35. Tavangar SM, Monajemzadeh M, Larijani B & Haghpanah V 2007 Immunohistochemical study of oestrogen receptors in 351 human thyroid glands. Singapore Medical Journal 48 744-747.
36. Vannucchi G, Perrino M, Rossi S, Colombo C, Vicentini L, Dazzi D, Beck-Peccoz P & Fugazzola L 2010 Clinical and molecular features of differentiated thyroid cancer diagnosed during pregnancy. European Journal of Endocrinology 162 145-151. (doi:10.1530/EJE-09-0761)
37. Zeng Q, Chen GG, Vlantis AC & van Hasselt CA 2007 Oestrogen mediates the growth of human thyroid carcinoma cells via an oestrogen receptor-ERK pathway. Cell Proliferation 40 921-935.
38. Zeng Q, Chen G, Vlantis A, Tse G & van Hasselt C 2008 The contributions of oestrogen receptor isoforms to the development of papillary and anaplastic thyroid carcinomas. Journal of Pathology 214 425-433. (doi:10.1002/ path.2297)
39. Zhai QH, Ruebel K, Thompson GB & Lloyd RV 2003 Androgen receptor expression in C-cells and in medullary thyroid carcinoma. Endocrine Pathology 14 159-165. (doi:10.1385/EP:14:2:159)